Hospital Privado de la Comunidad
Hospital Privado de la Comunidad
Córdoba 4545, Mar del Plata, Buenos Aires
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Pablo Capellino
Ignacio Alfredo Casarini
Álvaro Facta
Open studies
Bladder Cancer
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) - SunRISe-3 - Janssen Research & Development, LLCSee more
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) - SunRISe-5 - Janssen Research & Development, LLCSee more
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer - MoonRISe-1 - Janssen Research & Development, LLCSee more
Lung cancer
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations - TROPION-Lung08 - AstraZenecaSee more
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) - TROPION-Lung07 - AstraZenecaSee more
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib - COCOON - Janssen Research & Development, LLCSee more
Urothelial cancer
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations - THOR CR108401 - Janssen Research & Development, LLCSee more
